These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 27997513)

  • 1. SEMIAUTOMATED QUANTITATIVE APPROACH TO CHARACTERIZE TREATMENT RESPONSE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Real-World Study.
    Roberts PK; Nesper PL; Gill MK; Fawzi AA
    Retina; 2017 Aug; 37(8):1492-1498. PubMed ID: 27997513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
    Wada I; Oshima Y; Shiose S; Kano K; Nakao S; Kaizu Y; Yoshida S; Ishibashi T; Sonoda KH
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PROGRESSION OF MACULAR ATROPHY IN EYES WITH TYPE 1 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION RECEIVING LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: An Optical Coherence Tomographic Angiography Analysis.
    Christenbury JG; Phasukkijwatana N; Gilani F; Freund KB; Sadda S; Sarraf D
    Retina; 2018 Jul; 38(7):1276-1288. PubMed ID: 28723848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiling neovascular age-related macular degeneration choroidal neovascularization lesion response to anti-vascular endothelial growth factor therapy using SSOCTA.
    Told R; Reiter GS; Mittermüller TJ; Schranz M; Reumueller A; Schlanitz FG; Weigert G; Pollreisz A; Sacu S; Schmidt-Erfurth U
    Acta Ophthalmol; 2021 Mar; 99(2):e240-e246. PubMed ID: 32706171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting.
    Vardarinos A; Gupta N; Janjua R; Iron A; Empeslidis T; Tsaousis KT
    BMC Ophthalmol; 2017 Apr; 17(1):58. PubMed ID: 28449645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration.
    Barış ME; Menteş J; Afrashi F; Nalçaçı S; Akkın C
    Turk J Ophthalmol; 2020 Oct; 50(5):275-282. PubMed ID: 33342194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AGE-RELATED MACULAR DEGENERATION-ASSOCIATED PERIPAPILLARY CHOROIDAL NEOVASCULARIZATION IN THE ERA OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Lin T; Dans K; Meshi A; Muftuoglu IK; Amador-Patarroyo MJ; Chen KC; Cheng L; Freeman WR
    Retina; 2019 Oct; 39(10):1936-1944. PubMed ID: 30028411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMPLICATIONS OF THE MORPHOLOGIC PATTERNS OF TYPE 1 MACULAR NEOVASCULARIZATION ON MACULAR ATROPHY GROWTH ON PATIENTS UNDER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT.
    Cabral D; Coscas F; Pereira T; Laiginhas R; Rodrigues C; Français C; Nogueira V; Falcão M; Miere A; Lupidi M; Coscas G; Souied E
    Retina; 2021 Feb; 41(2):287-295. PubMed ID: 32355125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MACULAR ATROPHY FINDINGS BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY COMPARED WITH FUNDUS AUTOFLUORESCENCE IN TREATED EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    Takasago Y; Shiragami C; Kobayashi M; Osaka R; Ono A; Yamashita A; Tsujikawa A; Hirooka K
    Retina; 2019 Feb; 39(2):296-302. PubMed ID: 29190232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macular Atrophy Development and Subretinal Drusenoid Deposits in Anti-Vascular Endothelial Growth Factor Treated Age-Related Macular Degeneration.
    Zarubina AV; Gal-Or O; Huisingh CE; Owsley C; Freund KB
    Invest Ophthalmol Vis Sci; 2017 Dec; 58(14):6038-6045. PubMed ID: 29196768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced Vessel Density of the Choriocapillaris during Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration.
    Hikichi T; Agarie M
    Invest Ophthalmol Vis Sci; 2019 Mar; 60(4):1088-1095. PubMed ID: 30901385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in Fundus Autofluorescence after Anti-vascular Endothelial Growth Factor According to the Type of Choroidal Neovascularization in Age-related Macular Degeneration.
    Lee JY; Chung H; Kim HC
    Korean J Ophthalmol; 2016 Feb; 30(1):17-24. PubMed ID: 26865799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial.
    Fan W; Abdelfattah NS; Uji A; Lei J; Ip M; Sadda SR; Wykoff CC;
    Graefes Arch Clin Exp Ophthalmol; 2018 Mar; 256(3):511-518. PubMed ID: 29374796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optical coherence tomography angiography markers associated with treatment response in neovascular age-related macular degeneration.
    Ozdemir Zeydanli E; Gurelik G
    Eur J Ophthalmol; 2021 May; 31(3):1192-1200. PubMed ID: 32450717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration.
    Kanadani TCM; Dos Reis Veloso CE; Dorairaj S; Nehemy MB
    Ophthalmic Res; 2017; 58(1):18-26. PubMed ID: 28301850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHANGES IN EARLY TYPE 3 NEOVASCULARIZATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT.
    Miere A; Querques G; Semoun O; Amoroso F; Zambrowski O; Chapron T; Capuano V; Souied EH
    Retina; 2017 Oct; 37(10):1873-1879. PubMed ID: 28079756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Choroidal Topographic Changes by Swept-Source Optical Coherence Tomography After Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration.
    Razavi S; Souied EH; Darvizeh F; Querques G
    Am J Ophthalmol; 2015 Nov; 160(5):1006-13. PubMed ID: 26275471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Retinal Vessel Size Study of Intravitreal Ranibizumab and Bevacizumab in Eyes with Neovascular Age-Related Macular Degeneration.
    Kurt MM; Çekiç O; Akpolat Ç; Aslankurt M; Elçioğlu MN
    Ophthalmologica; 2017; 238(3):147-153. PubMed ID: 28601887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CHANGES IN OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY AND DISEASE ACTIVITY IN TYPE 3 NEOVASCULARIZATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT.
    Han JW; Cho HJ; Kang DH; Jung SH; Park S; Kim JW
    Retina; 2020 Jul; 40(7):1245-1254. PubMed ID: 31095063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. REGRESSION OF TYPE 2 NEOVASCULARIZATION INTO A TYPE 1 PATTERN AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Dolz-Marco R; Phasukkijwatana N; Sarraf D; Freund KB
    Retina; 2017 Feb; 37(2):222-233. PubMed ID: 27627752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.